Definium Therapeutics posts Phase 3 Voyage topline results presentation

• Definium Therapeutics published a Phase 3 Voyage topline results presentation for DT120 ODT in generalized anxiety disorder.
• Primary endpoint met, showing a 5.4-point HAM-A improvement versus placebo at week 12; p<0.0001; effect size 0.81.
• Rapid separation reported, including a 7.7-point HAM-A improvement versus placebo at week 1; p<0.0001.
• Safety through week 12 described as generally well tolerated; no new safety signals; no serious adverse events in the DT120 arm.
• Trial enrolled 214 participants, randomized 1:1 to a single 100 microgram dose of DT120 ODT or placebo in a 12-week double-blind period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.